Triferic® (ferric pyrophosphate citrate) – New Formulation Approval

• On April 26, 2016, Rockwell Medical announced the FDA approval of Triferic (ferric pyrophosphate citrate) for solution, indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).
  — Triferic is not intended for use in patients receiving peritoneal dialysis.
  — Triferic has not been studied in patients receiving home hemodialysis.

• Warnings and precautions for Triferic include hypersensitivity reactions and iron laboratory testing.

• Triferic for solution will be available as 272 mg of iron (III) per packet as Triferic powder.

• Triferic is also available as 27.2 mg of iron (III)/5 mL and 272 mg of iron (III)/50 mL solution.

• Both Triferic formulations have the same indication. They are added to bicarbonate concentrate and administered through the dialysate while patients are receiving hemodialysis.

• Rockwell Medical plans to launch Triferic for solution soon.